Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model

Background Despite widespread immunization programs, a clear increase in pertussis incidence is apparent in many developed countries during the last decades. Consequently, additional immunization strategies are considered to reduce the burden of disease. The aim of this study is to design an individual-based stochastic dynamic framework to model pertussis transmission in the population in order to predict the epidemiologic and economic consequences of the implementation of universal booster vaccination programs. Using this framework, we estimate the cost-effectiveness of universal adolescent pertussis booster vaccination at the age of 12 years in the Netherlands. Methods/Principal Findings We designed a discrete event simulation (DES) model to predict the epidemiological and economic consequences of implementing universal adolescent booster vaccination. We used national age-specific notification data over the period 1996–2000—corrected for underreporting—to calibrate the model assuming a steady state situation. Subsequently, booster vaccination was introduced. Input parameters of the model were derived from literature, national data sources (e.g. costing data, incidence and hospitalization data) and expert opinions. As there is no consensus on the duration of immunity acquired by natural infection, we considered two scenarios for this duration of protection (i.e. 8 and 15 years). In both scenarios, total pertussis incidence decreased as a result of adolescent vaccination. From a societal perspective, the cost-effectiveness was estimated at €4418/QALY (range: 3205–6364 € per QALY) and €6371/QALY (range: 4139–9549 € per QALY) for the 8- and 15-year protection scenarios, respectively. Sensitivity analyses revealed that the outcomes are most sensitive to the quality of life weights used for pertussis disease. Conclusions/Significance To our knowledge we designed the first individual-based dynamic framework to model pertussis transmission in the population. This study indicates that adolescent pertussis vaccination is likely to be a cost-effective intervention for The Netherlands. The model is suited to investigate further pertussis booster vaccination strategies.

[1]  D J Nokes,et al.  Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. , 1999, Statistics in medicine.

[2]  C. Farrington,et al.  Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods , 1993, Epidemiology and Infection.

[3]  C. Farrington,et al.  The measurement and interpretation of age-specific vaccine efficacy. , 1992, International journal of epidemiology.

[4]  I. Ortega-Sánchez,et al.  Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  P E Fine,et al.  Herd immunity: history, theory, practice. , 1993, Epidemiologic reviews.

[6]  Randall P. Sadowski,et al.  Simulation with Arena , 1998 .

[7]  Grace M. Lee,et al.  Cost-effectiveness of adult pertussis vaccination in Germany. , 2008, Vaccine.

[8]  B T Grenfell,et al.  The estimation of age-related rates of infection from case notifications and serological data , 1985, Journal of Hygiene.

[9]  M. Hanlon,et al.  Acellular vaccines for preventing whooping cough in children. , 1999, The Cochrane database of systematic reviews.

[10]  A. Hinman,et al.  Pertussis and pertussis vaccine: further analysis of benefits, risks and costs. , 1985, Developments in biological standardization.

[11]  A. Brennan,et al.  Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. , 2002, Vaccine.

[12]  P. Beutels,et al.  An economic evaluation of universal pertussis vaccination in Italy. , 1999, Vaccine.

[13]  M C Weinstein,et al.  Pertussis Vaccine: An Analysis of Benefits, Risks, and Costs , 1979, The New England journal of medicine.

[14]  Joel W Hay,et al.  Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  H. Hethcote,et al.  Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. , 1999, Mathematical biosciences.

[16]  M. Hemels,et al.  Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. , 2004, Vaccine.

[17]  M. van Boven,et al.  A model based evaluation of the 1996–7 pertussis epidemic in the Netherlands , 2001, Epidemiology and Infection.

[18]  J. Hedrick,et al.  Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents , 2006, Pediatrics.

[19]  T. Lieu,et al.  Societal costs and morbidity of pertussis in adolescents and adults. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Kretzschmar,et al.  Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. , 2006, American journal of epidemiology.

[21]  J. Schellekens,et al.  Pertussis Sources of Infection and Routes of Transmission in the Vaccination Era , 2005, The Pediatric infectious disease journal.

[22]  A. Hinman,et al.  Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs. , 1984, JAMA.

[23]  M. Brisson,et al.  Deaths from pertussis are underestimated in England , 2002, Archives of disease in childhood.

[24]  Susan Partridge,et al.  Efficacy of an acellular pertussis vaccine among adolescents and adults. , 2005, The New England journal of medicine.

[25]  T. Lieu,et al.  Cost effectiveness of pertussis vaccination in adults. , 2007, American journal of preventive medicine.

[26]  J. Roord,et al.  Laboratory‐confirmed reinfections with Bordetella pertussis , 2002, Acta paediatrica.

[27]  H. Hethcote,et al.  An age-structured model for pertussis transmission. , 1997, Mathematical biosciences.

[28]  P. Strebel,et al.  Underreporting of pertussis deaths in the United States: need for improved surveillance. , 1998, Pediatrics.

[29]  S. Halperin,et al.  Morbidity of pertussis in adolescents and adults. , 2000, The Journal of infectious diseases.

[30]  Mirjam Kretzschmar,et al.  The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. , 2006, The Journal of infection.

[31]  F. Mooi,et al.  Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. , 1997, Emerging infectious diseases.

[32]  J. Caro,et al.  Pertussis Immunization of Adolescents in the United States: An Economic Evaluation , 2005, The Pediatric infectious disease journal.

[33]  F. Mooi,et al.  Analysis of Bordetella pertussis Populations in European Countries with Different Vaccination Policies , 2005, Journal of Clinical Microbiology.

[34]  J. Salomon,et al.  Health and Quality of Life Outcomes Health-state Valuations for Pertussis: Methods for Valuing Short-term Health States Pertussistime Trade-offwillingness-to-payshort-term Health-state , 2022 .

[35]  W. Orenstein.  Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  E. Doorslaer,et al.  Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany , 1998, European Journal of Pediatrics.

[37]  A. Melegaro,et al.  The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. , 2002, Vaccine.

[38]  Lucia H. Lee,et al.  Costs of illness due to Bordetella pertussis in families. , 2000, Archives of family medicine.

[39]  M. van Boven,et al.  Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands. , 2000, Mathematical biosciences.

[40]  P. Kaye.  Infectious diseases of humans: Dynamics and control , 1993 .

[41]  M A Koopmanschap,et al.  The friction cost method for measuring indirect costs of disease. , 1995, Journal of health economics.

[42]  J. Roca,et al.  Prospective Multinational Study of Pertussis Infection in Hospitalized Infants and Their Household Contacts , 2007, The Pediatric infectious disease journal.

[43]  M. Postma,et al.  Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness? , 2004, Expert review of pharmacoeconomics & outcomes research.

[44]  S. Keam,et al.  Reduced-Antigen, Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine, Adsorbed (Boostrix® US Formulation) , 2006, Paediatric drugs.

[45]  Evelinda Trindade,et al.  Epidemiology of pertussis. , 2005, The Pediatric infectious disease journal.

[46]  Peter McIntyre,et al.  Using computer simulations to compare pertussis vaccination strategies in Australia. , 2004, Vaccine.

[47]  L. Coudeville,et al.  Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies , 2007, Epidemiology and Infection.

[48]  C. Mae,et al.  The pertussis epidemic in 1996; description and evaluation based on surveillance data from 1976 to 1996 , 1997 .

[49]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[50]  M. Meltzer,et al.  Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. , 2000, Archives of pediatrics & adolescent medicine.

[51]  Aaron M Wendelboe,et al.  Duration of Immunity Against Pertussis After Natural Infection or Vaccination , 2005, The Pediatric infectious disease journal.

[52]  T. Lieu,et al.  Pertussis in Adolescents and Adults: Should We Vaccinate? , 2005, Pediatrics.

[53]  E. Rothstein,et al.  Health Burden of Pertussis in Adolescents and Adults , 2005, The Pediatric infectious disease journal.

[54]  H. Hethcote,et al.  Adolescent and adult pertussis vaccination: computer simulations of five new strategies. , 2004, Vaccine.

[55]  Wytse J. Wadman,et al.  Health Council of the Netherlands: No need to change from SAR to time-temperature relation in electromagnetic fields exposure limits , 2011, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[56]  F. Mooi,et al.  [Pertussis in the Netherlands]. , 2010, Nederlands tijdschrift voor geneeskunde.

[57]  Jonathan Karnon,et al.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. , 2003, Health economics.

[58]  T. Einarson,et al.  Economic Evaluation of an Extended Acellular Pertussis Vaccine Program for Adolescents in Québec, Canada , 2005, Paediatric drugs.

[59]  William Hollingworth,et al.  Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation. , 2007, Academic radiology.

[60]  P. Scuffham,et al.  Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis. , 2004, Vaccine.

[61]  F. Simondon.  Systematic review of the effects of pertussis vaccines in children. , 2004, Vaccine.

[62]  F. Mooi,et al.  Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. , 2000, Emerging infectious diseases.

[63]  S. Halperin.  Canadian Experience With Implementation of an Acellular Pertussis Vaccine Booster-Dose Program in Adolescents: Implications for the United States , 2005, The Pediatric infectious disease journal.

[64]  T. Einarson,et al.  Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada , 2012, PharmacoEconomics.

[65]  W. Edmunds,et al.  Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[66]  M. Pichichero,et al.  Acellular Pertussis Vaccine Safety and Efficacy in Children, Adolescents and Adults , 2012, Drugs.

[67]  Jacco Wallinga,et al.  Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. , 2008, Vaccine.

[68]  J. Caro,et al.  Pharmacoeconomic analyses using discrete event simulation , 2012, PharmacoEconomics.